UNSPSC 51433928: Amlodipine mesylate hydrate

This classification denotes the hydrate form of a calcium channel blocker with the molecular formula C20H25CLN2O5.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 291Y33EZHA. European Medicines Agency schedules amlodipine mesylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22129. Most nations, for tariff and trade purposes, schedule amlodipine mesylate hydrate under HS 29333999. SMILES: CCOC(=O)C1=C(NC(=C(C1C2CCCCC2CL)C(=O)OC)C)COCCN.CS(=O)(=O)O.O.

UNSPSC 51433928 Amlodipine mesylate hydrate is a Commodity code covering active pharmaceutical ingredients and finished medications used by state and local emergency medical services, public health agencies, and cooperative purchasing coalitions. State and local governments buy this code as part of broader advanced life support medication portfolios for fire rescue operations, hospital systems, and multi-jurisdictional pharmaceutical supply programs. Recent solicitations show purchasing departments acquiring amlodipine mesylate hydrate alongside other cardiovascular and emergency medications—labetalol, epinephrine, adenosine, and diltiazem—for emergency medical use rather than as a standalone drug product. Issuing bodies include city purchasing departments acting on behalf of fire rescue services, state health and human services commissions managing pharmacy benefit programs, and multistate cooperative purchasing alliances coordinating pharmaceutical sourcing across member agencies and jurisdictions.

Activity concentrates in Florida and Minnesota with emerging interest in Texas. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications with response deadline April 8, 2026, seeking 1,020 units of diltiazem and three companion medications for Tampa Fire Rescue at an estimated contract value of $40,000.00, with a five-percent bid discount available for Small Local Business Enterprise participation. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products with response deadline March 26, 2026, requiring vendor pricing, NDC submissions, and relationships with authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, Morris & Dickson Co.), with evaluation weighted 75 percent on price competitiveness and contracts effective July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 on a preliminary basis in early April 2026 to gather vendor capabilities for direct-to-manufacturer prescription fulfillment, signaling future formal solicitations for pharmacy benefit program innovation.